Although Evidence-based medicine (EBM) and Patient-centered medicine (PCM) are often perceived as two conflicting paradigms that speak the language of populations and the language of individuals, respectively, both share the common objective of improving the care of individual patients. As physicians should not practice an EBM that is away from the individual patient nor a PCM that is not based on the best available evidence, it is crucial to connect and combine both movements, promoting the fruitful and natural interaction between research and care. Achieving such interaction requires developing new individual-patient centric research methods. In this commentary, we propose an innovative clinical research design oriented to personalize point-of-care trials-integrating clinical research and medical care-through the incorporation of individual patients' preferences to build personalized research protocols. Building on the framework of N-of-1 studies, in "individual point-of-care trials," each protocol could be personalized for each patient so that the therapeutic objectives, the outcome variables analyzed, and the (operationalization of the) compared interventions would be based not only on the clinical and biological characteristics of each patient but also on their individual preferences, goals, and values. If patient preferences are being progressively integrated into medical practice, it makes sense that they also are incorporated into clinical trials embedded in care delivery. The proposal to perform individual point of care trials may be an optimal way to combine EBM and PCM while preserving their foundational principles, and to ensure the connection between "personalized" and "personal" care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jclinepi.2020.09.038 | DOI Listing |
Br J Nurs
January 2025
Department of Psychology, Faculty of Arts, University of Calgary, Alberta, Canada; Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta, Canada; Ward of the 21st Century, Cumming School of Medicine, University of Calgary, Alberta, Canada.
Introduction: Peripheral intravenous cannulation (PIVC) is a common and complex procedure with low first-attempt success rates, causing patient suffering and increased healthcare costs. Quiet Eye (QE) training, a gaze-focused approach, has shown promise in improving procedural PIVC skills. We will examine the effectiveness of traditional technical training (TT) and QE training (QET) on student nurse PIVC performance.
View Article and Find Full Text PDFWest Afr J Med
September 2024
.Department of Preventive Dentistry, Lagos State University, College of Medicine, Faculty of Dentistry, Ikeja, Lagos, PMB 21266, Nigeria.
Background: Indirect pulp capping is the main treatment modality for reversible pulpitis.
Objective: To evaluate the efficacy of Biodentine® and Calcium hydroxide in the formation of dentin bridge.
Materials And Methods: A double blinded, randomized clinical control trial involving 50 consenting subjects, aged 16 to 55 years with deep carious vital teeth.
Ann Med
December 2025
Heart Centre, Turku University Hospital, Turku, Finland.
Background: Several randomized controlled trials (RCTs) have investigated the benefits of atrial fibrillation (AF) screening. However, since none have shown a significant reduction in stroke rates, the impact of screening on clinical outcomes remains uncertain.
Materials And Methods: We conducted a systematic review and meta-analysis of RCTs reporting clinical outcomes of systematic AF screening in participants without known AF.
Dermatol Ther (Heidelb)
January 2025
Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit "Daniele Innocenzi", "Sapienza" University of Rome, Polo Pontino, 04100, Latina, Italy.
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus and a relapsing course, affecting approximately 25% of children and 4-7% of adults. This study evaluated the efficacy, safety, and quality-of-life impact of tralokinumab, a humanized monoclonal antibody targeting interleukin-13 (IL-13), in treating moderate-to-severe AD in a real-world setting, with a focus on different AD phenotypes.
Methods: An observational cohort of 30 adults treated with tralokinumab for ≥ 16 weeks was analyzed.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!